by Dr. Stéphanie Durand-Panteix, CRIBL Lab CNRS7276/INSERM1262/University of Limoges, France
This webinar highlights the potency of 212Pb-alpha radioimmunotherapy in Multiple Myeloma treatment. The results of this study showed the efficacy of 212Pb-daratumumab in xenografted mice with significant tumor regression and increased survival. To conduct this preclinical study, we performed in vivo biodistribution study using USPECT4CT. Results obtained by whole-body SPECT/CT images using 203Pb, a gamma-emitter, allowed to consider a theranostic approach for 212Pb alpha-therapy with a chemically identical radioelement.
Took place: October, 2020
You may also like
Each DNA damage repair pathway leads to the recruitment, upregulation, or activation of specific proteins within the nucleus, which, in some cases, can represent attractive targets for molecular imaging.
For a detailed biodistribution analysis, PET and SPECT are usually preferred as they are more accurate and quantitative, so the question is, can optical imaging become a complementary tool for pre-clinical biodistribution analysis.
Marko Rosenholm presents some of the findings and results regarding dynamic SPECT/CT imaging of a glymphatic system they have acquired with the MILabs VECTor/CT system.
